ISポスター発表3 IS3

[ISP-011] ENGOT-en9/LEAP-001：A Phase 3 Study of Pembrolizumab Plus Lenvatinib Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Cancer

Kosei Hasegawa¹, Christian Marth², Christof Vulsteke³, J.Maria Rubio⁴, Vicky Makker⁵, I.Elana Braicu⁶, Iain McNeish⁷, Radoslaw Madry⁸, Ali Ayhan⁹, Xiaohua Wu¹⁰, Lea Dutta¹¹, Cindy Xu¹², Stephen Keefe¹², John Lee¹², Sandro Pignata¹³ (1.Department of Gynecologic Oncology, Saitama Medical University, Hidaka, Saitama Prefecture, Japan, 2.Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria, 3.AZ Maria Middelares, Center for Oncological Research（CORE）, Antwerp University, Gent, Belgium, 4.H. Reina Sofia de Cordoba, Cordoba, Spain, 5.Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA, 6.Department of Gynecology, Campus Virchow Clinic, Charite Universitatsmedizin Berlin, Berlin, Germany, 7.Department of Surgery and Cancer, Imperial College, London, UK, 8.Uniwersytet Medyczny im K. Marcinkowskiego w Poznaniu, Poznan, Poland, 9.Ankara Baskent University Hospital, Ankara, Turkey, 10.Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, 11.Eisai Inc., Woodcliff Lake, NJ, USA, 12.Merck ＆ Co., Inc., Kenilworth, NJ, USA, 13.Uro-Gynecological Department, National Cancer Institute, Napoli, Italy)